Noninvasive early detection and recurrence monitoring for non-muscle-invasive bladder cancer via urine tumor DNA.

• DOI: 10.1200/jco.2024.42.16_suppl.e16586
• Publication Date: 2024-06-06T17:50:18Z
• Authors: Junlong Wu; Huanqing Cheng; Huina Wang; Libin Chen; Lei Liu; Shanbo Cao; Feng Lou; Ding-Wei Ye
• Keywords: 03 medical and health sciences; 0302 clinical medicine

e16586 Background: Traditional methods for the detection and surveillance of non-muscle-invasive bladder cancer (NMIBC) were generally invasive, costly, not effective early-stage, low-grade, minimal residual disease (MRD) tumors. Whether urine tumor DNA could be used to early detect urothelial carcinoma monitor MRD with high sensitivity should explored. Methods: We conducted a perspective study determine performance utLIFE-UC (our previously reported multidimensional bioinformatic predictor) in recurrence monitoring NMIBC (Trial No. ChiCTR2300072635). prospectively recruited 49 patients initially diagnosed NMIBC. Urine samples collected prior transurethral resection (TURBT) repeat TURBT (Re-TURBT) if needed. Postsurgical every 3-6 months when underwent routine cystoscopy. The score > 60 indicates positive clinical significance. Results: Overall, discriminate sensitivities 91.8% (45/49), both different T stages (Ta, 84.0%; T1, 100%; P = 0.110) grades (low-grade, 88.2%; high-grade, 93.3%; 0.613). Twenty Re-TURBT, whom 8 cases had tumor. correctly (100%) In addition, assay showed NPV 100%, implying that it may aid avoiding Re-TURBT predicted have no Notably, before multiple tumors (MT) was markedly increased than single (ST) (P 0.028). MRD-positive rate MT whereas 50% ST MRD-negative. During follow-up, status 27 collected, 18.5% (5/27) them recurred. median follow-up time 211 days (range 39 326 days). For receiving all MRD-negative results recurrence, further supporting possible unnecessity this population. prognostic value postsurgical worse recurrence-free survival ones (median 200 vs unreached; 0.001). However, observed correlation between prognosis features, including age, sex, number, stage, grade. Compared confirmed predict lead 100 17 140 days; 0.056). Conclusions: TheutLIFE-UC diagnosis, is noninvasive approach, which contribute reducing burden cystoscopy invasive examination. Clinical trial information: ChiCTR2300072635 .